# PeptideScanner evidence objects: Orforglipron

Every published version of the records placed with Orforglipron, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/orforglipron.json. Selected public evidence only; not medical advice.

- Objects: 33
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct05869903-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT05869903

> PeptideScanner retained ClinicalTrials.gov record NCT05869903 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-08-14, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct05869903-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05869903-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct05869903-orforglipron-v1
- Content SHA-256: `7447a62b4230e35347269f5ab4e2798fff22b29338bb2ebd9947c6d80d2ed73d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05869903 ([`ctg-observation-nct05869903-2026-08-14-650d7c281987`](#source-ctg-observation-nct05869903-2026-08-14-650d7c281987))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05869903 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-08-14, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct05869903-2026-08-14-650d7c281987`](#source-ctg-observation-nct05869903-2026-08-14-650d7c281987))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05869903 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-08-14, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct05869903-2026-08-14-650d7c281987`](#source-ctg-observation-nct05869903-2026-08-14-650d7c281987))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05869903-2026-08-14-650d7c281987`](#source-ctg-observation-nct05869903-2026-08-14-650d7c281987))

### Sources

<a id="source-ctg-observation-nct05869903-2026-08-14-650d7c281987"></a>
- **ClinicalTrials.gov record NCT05869903 · retained source version 2026-08-14:650d7c2819872ef0fea318709542ccc13485fe54f56741e8b8941e98570fefcd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05869903) (`ctg-observation-nct05869903-2026-08-14-650d7c281987`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05869903." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct05869903-orforglipron-v1 SHA-256: 7447a62b4230e35347269f5ab4e2798fff22b29338bb2ebd9947c6d80d2ed73d.

---

<a id="clinicaltrials-gov-nct05872620-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT05872620

> PeptideScanner retained ClinicalTrials.gov record NCT05872620 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct05872620-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05872620-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct05872620-orforglipron-v1
- Content SHA-256: `9f8c76b67242422f52fb968f4e0cbb5b1752b03772fb7b1bbd22b285d31bd6b9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05872620 ([`ctg-observation-nct05872620-2026-09-04-4f534ed1ca04`](#source-ctg-observation-nct05872620-2026-09-04-4f534ed1ca04))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05872620 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct05872620-2026-09-04-4f534ed1ca04`](#source-ctg-observation-nct05872620-2026-09-04-4f534ed1ca04))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05872620 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct05872620-2026-09-04-4f534ed1ca04`](#source-ctg-observation-nct05872620-2026-09-04-4f534ed1ca04))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05872620-2026-09-04-4f534ed1ca04`](#source-ctg-observation-nct05872620-2026-09-04-4f534ed1ca04))

### Sources

<a id="source-ctg-observation-nct05872620-2026-09-04-4f534ed1ca04"></a>
- **ClinicalTrials.gov record NCT05872620 · retained source version 2026-09-04:4f534ed1ca048f1b35f7bc5a2fafe5bac299316d05924bd32fc4302f59758577** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05872620) (`ctg-observation-nct05872620-2026-09-04-4f534ed1ca04`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05872620." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct05872620-orforglipron-v1 SHA-256: 9f8c76b67242422f52fb968f4e0cbb5b1752b03772fb7b1bbd22b285d31bd6b9.

---

<a id="clinicaltrials-gov-nct05931380-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT05931380

> PeptideScanner retained ClinicalTrials.gov record NCT05931380 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct05931380-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05931380-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct05931380-orforglipron-v1
- Content SHA-256: `dbcc44382d5be210409e5383ee6de59a5a8846a03f8750037e578e700e842b8c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05931380 ([`ctg-observation-nct05931380-2026-07-20-2d642b7a2f34`](#source-ctg-observation-nct05931380-2026-07-20-2d642b7a2f34))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05931380 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct05931380-2026-07-20-2d642b7a2f34`](#source-ctg-observation-nct05931380-2026-07-20-2d642b7a2f34))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05931380 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct05931380-2026-07-20-2d642b7a2f34`](#source-ctg-observation-nct05931380-2026-07-20-2d642b7a2f34))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05931380-2026-07-20-2d642b7a2f34`](#source-ctg-observation-nct05931380-2026-07-20-2d642b7a2f34))

### Sources

<a id="source-ctg-observation-nct05931380-2026-07-20-2d642b7a2f34"></a>
- **ClinicalTrials.gov record NCT05931380 · retained source version 2026-07-20:2d642b7a2f348bc6ed252e14da168735e5727bb87f276b1c325d47deaca0c514** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05931380) (`ctg-observation-nct05931380-2026-07-20-2d642b7a2f34`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05931380." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct05931380-orforglipron-v1 SHA-256: dbcc44382d5be210409e5383ee6de59a5a8846a03f8750037e578e700e842b8c.

---

<a id="clinicaltrials-gov-nct05971940-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT05971940

> PeptideScanner retained ClinicalTrials.gov record NCT05971940 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct05971940-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05971940-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct05971940-orforglipron-v1
- Content SHA-256: `87f50b39b7edffeba93bc73e1d60fdc17e1819bda2f96580c81c3617c6d7b960`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05971940 ([`ctg-observation-nct05971940-2026-09-03-a1388b0f3170`](#source-ctg-observation-nct05971940-2026-09-03-a1388b0f3170))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05971940 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct05971940-2026-09-03-a1388b0f3170`](#source-ctg-observation-nct05971940-2026-09-03-a1388b0f3170))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05971940 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct05971940-2026-09-03-a1388b0f3170`](#source-ctg-observation-nct05971940-2026-09-03-a1388b0f3170))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05971940-2026-09-03-a1388b0f3170`](#source-ctg-observation-nct05971940-2026-09-03-a1388b0f3170))

### Sources

<a id="source-ctg-observation-nct05971940-2026-09-03-a1388b0f3170"></a>
- **ClinicalTrials.gov record NCT05971940 · retained source version 2026-09-03:a1388b0f31700eea781e04cdcf996aabf310b247ed2d71daab20364015c6b9c8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05971940) (`ctg-observation-nct05971940-2026-09-03-a1388b0f3170`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05971940." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct05971940-orforglipron-v1 SHA-256: 87f50b39b7edffeba93bc73e1d60fdc17e1819bda2f96580c81c3617c6d7b960.

---

<a id="clinicaltrials-gov-nct06010004-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT06010004

> PeptideScanner retained ClinicalTrials.gov record NCT06010004 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-06-30, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct06010004-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06010004-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06010004-orforglipron-v1
- Content SHA-256: `c050aeaf298ecd06bc48a277892996ef20a852361dd4f99be616a1bd453bad5d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06010004 ([`ctg-observation-nct06010004-2026-06-30-1adde0629026`](#source-ctg-observation-nct06010004-2026-06-30-1adde0629026))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06010004 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-06-30, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06010004-2026-06-30-1adde0629026`](#source-ctg-observation-nct06010004-2026-06-30-1adde0629026))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06010004 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-06-30, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06010004-2026-06-30-1adde0629026`](#source-ctg-observation-nct06010004-2026-06-30-1adde0629026))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06010004-2026-06-30-1adde0629026`](#source-ctg-observation-nct06010004-2026-06-30-1adde0629026))

### Sources

<a id="source-ctg-observation-nct06010004-2026-06-30-1adde0629026"></a>
- **ClinicalTrials.gov record NCT06010004 · retained source version 2026-06-30:1adde0629026d54c0832da7097cd0974eb7947eb663d91af944911e1c9c236f7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06010004) (`ctg-observation-nct06010004-2026-06-30-1adde0629026`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06010004." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06010004-orforglipron-v1 SHA-256: c050aeaf298ecd06bc48a277892996ef20a852361dd4f99be616a1bd453bad5d.

---

<a id="clinicaltrials-gov-nct06109311-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT06109311

> PeptideScanner retained ClinicalTrials.gov record NCT06109311 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-01, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct06109311-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06109311-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06109311-orforglipron-v1
- Content SHA-256: `448c136020eb5c6c9e18ede418fb66e6893c03c3bb6958b21b08e83d0db9b9d6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06109311 ([`ctg-observation-nct06109311-2026-10-01-134c016d92c6`](#source-ctg-observation-nct06109311-2026-10-01-134c016d92c6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06109311 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-01, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06109311-2026-10-01-134c016d92c6`](#source-ctg-observation-nct06109311-2026-10-01-134c016d92c6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06109311 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-01, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06109311-2026-10-01-134c016d92c6`](#source-ctg-observation-nct06109311-2026-10-01-134c016d92c6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06109311-2026-10-01-134c016d92c6`](#source-ctg-observation-nct06109311-2026-10-01-134c016d92c6))

### Sources

<a id="source-ctg-observation-nct06109311-2026-10-01-134c016d92c6"></a>
- **ClinicalTrials.gov record NCT06109311 · retained source version 2026-10-01:134c016d92c6ae12ebe38c0a6fd09b7e24725abfbf3446e92523334d5eb07dc3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06109311) (`ctg-observation-nct06109311-2026-10-01-134c016d92c6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06109311." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06109311-orforglipron-v1 SHA-256: 448c136020eb5c6c9e18ede418fb66e6893c03c3bb6958b21b08e83d0db9b9d6.

---

<a id="clinicaltrials-gov-nct06186622-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT06186622

> PeptideScanner retained ClinicalTrials.gov record NCT06186622 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct06186622-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06186622-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06186622-orforglipron-v1
- Content SHA-256: `44d7a5443c23afef9067963342de41fff98b37760206d04f2feb860be9754e5e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06186622 ([`ctg-observation-nct06186622-2026-05-22-e56f797871c1`](#source-ctg-observation-nct06186622-2026-05-22-e56f797871c1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06186622 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06186622-2026-05-22-e56f797871c1`](#source-ctg-observation-nct06186622-2026-05-22-e56f797871c1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06186622 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06186622-2026-05-22-e56f797871c1`](#source-ctg-observation-nct06186622-2026-05-22-e56f797871c1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06186622-2026-05-22-e56f797871c1`](#source-ctg-observation-nct06186622-2026-05-22-e56f797871c1))

### Sources

<a id="source-ctg-observation-nct06186622-2026-05-22-e56f797871c1"></a>
- **ClinicalTrials.gov record NCT06186622 · retained source version 2026-05-22:e56f797871c111d351137fbe9da048795174ce7a27f81e5d771908661a467748** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06186622) (`ctg-observation-nct06186622-2026-05-22-e56f797871c1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06186622." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06186622-orforglipron-v1 SHA-256: 44d7a5443c23afef9067963342de41fff98b37760206d04f2feb860be9754e5e.

---

<a id="clinicaltrials-gov-nct06192108-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT06192108

> PeptideScanner retained ClinicalTrials.gov record NCT06192108 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct06192108-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06192108-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06192108-orforglipron-v1
- Content SHA-256: `8112fec04b16882180ee031aac540050526efb39babee8b200b78e03f6e710ff`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06192108 ([`ctg-observation-nct06192108-2026-10-16-66b3e999a0a5`](#source-ctg-observation-nct06192108-2026-10-16-66b3e999a0a5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06192108 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06192108-2026-10-16-66b3e999a0a5`](#source-ctg-observation-nct06192108-2026-10-16-66b3e999a0a5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06192108 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06192108-2026-10-16-66b3e999a0a5`](#source-ctg-observation-nct06192108-2026-10-16-66b3e999a0a5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06192108-2026-10-16-66b3e999a0a5`](#source-ctg-observation-nct06192108-2026-10-16-66b3e999a0a5))

### Sources

<a id="source-ctg-observation-nct06192108-2026-10-16-66b3e999a0a5"></a>
- **ClinicalTrials.gov record NCT06192108 · retained source version 2026-10-16:66b3e999a0a57bcc847f23fb7b61435f8858580e9e087224081607a3faac42f6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06192108) (`ctg-observation-nct06192108-2026-10-16-66b3e999a0a5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06192108." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06192108-orforglipron-v1 SHA-256: 8112fec04b16882180ee031aac540050526efb39babee8b200b78e03f6e710ff.

---

<a id="clinicaltrials-gov-nct06370728-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT06370728

> PeptideScanner retained ClinicalTrials.gov record NCT06370728 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct06370728-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06370728-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06370728-orforglipron-v1
- Content SHA-256: `cd23fb924fed0ee9cd24f51eecf7d3109477d352e056cb09bbdd1d536a7d56aa`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06370728 ([`ctg-observation-nct06370728-2026-07-17-bc71f3e49a37`](#source-ctg-observation-nct06370728-2026-07-17-bc71f3e49a37))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06370728 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06370728-2026-07-17-bc71f3e49a37`](#source-ctg-observation-nct06370728-2026-07-17-bc71f3e49a37))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06370728 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06370728-2026-07-17-bc71f3e49a37`](#source-ctg-observation-nct06370728-2026-07-17-bc71f3e49a37))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06370728-2026-07-17-bc71f3e49a37`](#source-ctg-observation-nct06370728-2026-07-17-bc71f3e49a37))

### Sources

<a id="source-ctg-observation-nct06370728-2026-07-17-bc71f3e49a37"></a>
- **ClinicalTrials.gov record NCT06370728 · retained source version 2026-07-17:bc71f3e49a379c830921cbcf0809d7c7f89cf9bdd251aa8c81b3e1d8dfdbd14c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06370728) (`ctg-observation-nct06370728-2026-07-17-bc71f3e49a37`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06370728." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06370728-orforglipron-v1 SHA-256: cd23fb924fed0ee9cd24f51eecf7d3109477d352e056cb09bbdd1d536a7d56aa.

---

<a id="clinicaltrials-gov-nct06440980-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT06440980

> PeptideScanner retained ClinicalTrials.gov record NCT06440980 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct06440980-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06440980-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06440980-orforglipron-v1
- Content SHA-256: `f6d18e0b0609e1cdac232c804575d70247f940975b5e5c0ba34b93866c052f75`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06440980 ([`ctg-observation-nct06440980-2026-07-17-2d4cddaa7467`](#source-ctg-observation-nct06440980-2026-07-17-2d4cddaa7467))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06440980 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06440980-2026-07-17-2d4cddaa7467`](#source-ctg-observation-nct06440980-2026-07-17-2d4cddaa7467))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06440980 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06440980-2026-07-17-2d4cddaa7467`](#source-ctg-observation-nct06440980-2026-07-17-2d4cddaa7467))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06440980-2026-07-17-2d4cddaa7467`](#source-ctg-observation-nct06440980-2026-07-17-2d4cddaa7467))

### Sources

<a id="source-ctg-observation-nct06440980-2026-07-17-2d4cddaa7467"></a>
- **ClinicalTrials.gov record NCT06440980 · retained source version 2026-07-17:2d4cddaa74677b00577ee0e53b5e24a13766d8ade8dd973044f004784fd8a9f5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06440980) (`ctg-observation-nct06440980-2026-07-17-2d4cddaa7467`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06440980." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06440980-orforglipron-v1 SHA-256: f6d18e0b0609e1cdac232c804575d70247f940975b5e5c0ba34b93866c052f75.

---

<a id="clinicaltrials-gov-nct06649045-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT06649045

> PeptideScanner retained ClinicalTrials.gov record NCT06649045 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-14, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct06649045-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06649045-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06649045-orforglipron-v1
- Content SHA-256: `e8a5d69b9cb1309a9867757a7c3591b19da0ceb88855006dd0fddc3b83dcb6cc`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06649045 ([`ctg-observation-nct06649045-2026-09-14-207838ab6d88`](#source-ctg-observation-nct06649045-2026-09-14-207838ab6d88))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06649045 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-14, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06649045-2026-09-14-207838ab6d88`](#source-ctg-observation-nct06649045-2026-09-14-207838ab6d88))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06649045 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-14, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06649045-2026-09-14-207838ab6d88`](#source-ctg-observation-nct06649045-2026-09-14-207838ab6d88))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06649045-2026-09-14-207838ab6d88`](#source-ctg-observation-nct06649045-2026-09-14-207838ab6d88))

### Sources

<a id="source-ctg-observation-nct06649045-2026-09-14-207838ab6d88"></a>
- **ClinicalTrials.gov record NCT06649045 · retained source version 2026-09-14:207838ab6d8848719f36836d4d4c7daf4fe6b311f99d213565488ba5217947ff** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06649045) (`ctg-observation-nct06649045-2026-09-14-207838ab6d88`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06649045." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06649045-orforglipron-v1 SHA-256: e8a5d69b9cb1309a9867757a7c3591b19da0ceb88855006dd0fddc3b83dcb6cc.

---

<a id="clinicaltrials-gov-nct06672549-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT06672549

> PeptideScanner retained ClinicalTrials.gov record NCT06672549 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct06672549-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06672549-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06672549-orforglipron-v1
- Content SHA-256: `b149f3de7bb3a27d38b0668c345205b556a41f23199912b9527c4ddbba6d66bc`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06672549 ([`ctg-observation-nct06672549-2026-11-04-2aaf76a9bade`](#source-ctg-observation-nct06672549-2026-11-04-2aaf76a9bade))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06672549 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06672549-2026-11-04-2aaf76a9bade`](#source-ctg-observation-nct06672549-2026-11-04-2aaf76a9bade))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06672549 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06672549-2026-11-04-2aaf76a9bade`](#source-ctg-observation-nct06672549-2026-11-04-2aaf76a9bade))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06672549-2026-11-04-2aaf76a9bade`](#source-ctg-observation-nct06672549-2026-11-04-2aaf76a9bade))

### Sources

<a id="source-ctg-observation-nct06672549-2026-11-04-2aaf76a9bade"></a>
- **ClinicalTrials.gov record NCT06672549 · retained source version 2026-11-04:2aaf76a9bade39e441010e60dc89ac5a715bd5b82e903948a66fad44f10698fb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06672549) (`ctg-observation-nct06672549-2026-11-04-2aaf76a9bade`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06672549." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06672549-orforglipron-v1 SHA-256: b149f3de7bb3a27d38b0668c345205b556a41f23199912b9527c4ddbba6d66bc.

---

<a id="clinicaltrials-gov-nct06672939-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT06672939

> PeptideScanner retained ClinicalTrials.gov record NCT06672939 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct06672939-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06672939-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06672939-orforglipron-v1
- Content SHA-256: `b3080a626e4a423139053cfa8a94bc8cd4c4943d1209bdb366e03a6a4c1daa9b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06672939 ([`ctg-observation-nct06672939-2026-11-04-9b372fe8721e`](#source-ctg-observation-nct06672939-2026-11-04-9b372fe8721e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06672939 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06672939-2026-11-04-9b372fe8721e`](#source-ctg-observation-nct06672939-2026-11-04-9b372fe8721e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06672939 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06672939-2026-11-04-9b372fe8721e`](#source-ctg-observation-nct06672939-2026-11-04-9b372fe8721e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06672939-2026-11-04-9b372fe8721e`](#source-ctg-observation-nct06672939-2026-11-04-9b372fe8721e))

### Sources

<a id="source-ctg-observation-nct06672939-2026-11-04-9b372fe8721e"></a>
- **ClinicalTrials.gov record NCT06672939 · retained source version 2026-11-04:9b372fe8721ef4599a20396f52ae2d62f495708dc86a023c9cdf467aa1a4d3a9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06672939) (`ctg-observation-nct06672939-2026-11-04-9b372fe8721e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06672939." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06672939-orforglipron-v1 SHA-256: b3080a626e4a423139053cfa8a94bc8cd4c4943d1209bdb366e03a6a4c1daa9b.

---

<a id="clinicaltrials-gov-nct06704763-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT06704763

> PeptideScanner retained ClinicalTrials.gov record NCT06704763 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-05-26, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct06704763-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06704763-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06704763-orforglipron-v1
- Content SHA-256: `cf30139d156d9e3f9789d07cb4ce6fc4b78552384742ebcf75f139383dff6c9c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06704763 ([`ctg-observation-nct06704763-2026-05-26-68ef121fd10d`](#source-ctg-observation-nct06704763-2026-05-26-68ef121fd10d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06704763 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-05-26, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06704763-2026-05-26-68ef121fd10d`](#source-ctg-observation-nct06704763-2026-05-26-68ef121fd10d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06704763 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-05-26, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06704763-2026-05-26-68ef121fd10d`](#source-ctg-observation-nct06704763-2026-05-26-68ef121fd10d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06704763-2026-05-26-68ef121fd10d`](#source-ctg-observation-nct06704763-2026-05-26-68ef121fd10d))

### Sources

<a id="source-ctg-observation-nct06704763-2026-05-26-68ef121fd10d"></a>
- **ClinicalTrials.gov record NCT06704763 · retained source version 2026-05-26:68ef121fd10d085d538d8530980c4356e11b9d84a3c40c26ce330fc7929bf792** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06704763) (`ctg-observation-nct06704763-2026-05-26-68ef121fd10d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06704763." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06704763-orforglipron-v1 SHA-256: cf30139d156d9e3f9789d07cb4ce6fc4b78552384742ebcf75f139383dff6c9c.

---

<a id="clinicaltrials-gov-nct06972459-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT06972459

> PeptideScanner retained ClinicalTrials.gov record NCT06972459 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct06972459-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06972459-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06972459-orforglipron-v1
- Content SHA-256: `d0272fd3cffa996706d51a7214304f825383029f2c41dc820cc3050567942f3f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06972459 ([`ctg-observation-nct06972459-2026-07-29-0b5c98f4f7a4`](#source-ctg-observation-nct06972459-2026-07-29-0b5c98f4f7a4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06972459 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06972459-2026-07-29-0b5c98f4f7a4`](#source-ctg-observation-nct06972459-2026-07-29-0b5c98f4f7a4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06972459 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06972459-2026-07-29-0b5c98f4f7a4`](#source-ctg-observation-nct06972459-2026-07-29-0b5c98f4f7a4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06972459-2026-07-29-0b5c98f4f7a4`](#source-ctg-observation-nct06972459-2026-07-29-0b5c98f4f7a4))

### Sources

<a id="source-ctg-observation-nct06972459-2026-07-29-0b5c98f4f7a4"></a>
- **ClinicalTrials.gov record NCT06972459 · retained source version 2026-07-29:0b5c98f4f7a4fa5dfc3930850dbce252b8113286a5f5789c6f79e99cd8c394ca** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06972459) (`ctg-observation-nct06972459-2026-07-29-0b5c98f4f7a4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06972459." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06972459-orforglipron-v1 SHA-256: d0272fd3cffa996706d51a7214304f825383029f2c41dc820cc3050567942f3f.

---

<a id="clinicaltrials-gov-nct06993792-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT06993792

> PeptideScanner retained ClinicalTrials.gov record NCT06993792 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct06993792-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06993792-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06993792-orforglipron-v1
- Content SHA-256: `9e9608f87a3c837b149a068256ecd9b64790f4fd148d0c5e598b22302dcc5f54`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06993792 ([`ctg-observation-nct06993792-2026-07-31-41d9194b5e2e`](#source-ctg-observation-nct06993792-2026-07-31-41d9194b5e2e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06993792 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06993792-2026-07-31-41d9194b5e2e`](#source-ctg-observation-nct06993792-2026-07-31-41d9194b5e2e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06993792 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct06993792-2026-07-31-41d9194b5e2e`](#source-ctg-observation-nct06993792-2026-07-31-41d9194b5e2e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06993792-2026-07-31-41d9194b5e2e`](#source-ctg-observation-nct06993792-2026-07-31-41d9194b5e2e))

### Sources

<a id="source-ctg-observation-nct06993792-2026-07-31-41d9194b5e2e"></a>
- **ClinicalTrials.gov record NCT06993792 · retained source version 2026-07-31:41d9194b5e2e67a34bb238dc2c796cf7aeb3afb9318c2c502f034cff6655520a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06993792) (`ctg-observation-nct06993792-2026-07-31-41d9194b5e2e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06993792." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct06993792-orforglipron-v1 SHA-256: 9e9608f87a3c837b149a068256ecd9b64790f4fd148d0c5e598b22302dcc5f54.

---

<a id="clinicaltrials-gov-nct07153471-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT07153471

> PeptideScanner retained ClinicalTrials.gov record NCT07153471 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct07153471-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07153471-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07153471-orforglipron-v1
- Content SHA-256: `2edfa2430268ff4277c37daae8646da3ffb45d7c678c106122a7e9e71d67498b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07153471 ([`ctg-observation-nct07153471-2026-10-08-73cc3099cfd4`](#source-ctg-observation-nct07153471-2026-10-08-73cc3099cfd4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07153471 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07153471-2026-10-08-73cc3099cfd4`](#source-ctg-observation-nct07153471-2026-10-08-73cc3099cfd4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07153471 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07153471-2026-10-08-73cc3099cfd4`](#source-ctg-observation-nct07153471-2026-10-08-73cc3099cfd4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07153471-2026-10-08-73cc3099cfd4`](#source-ctg-observation-nct07153471-2026-10-08-73cc3099cfd4))

### Sources

<a id="source-ctg-observation-nct07153471-2026-10-08-73cc3099cfd4"></a>
- **ClinicalTrials.gov record NCT07153471 · retained source version 2026-10-08:73cc3099cfd464fcf4384e100f10ce4c88894c7a613b557f77c01302ad93159d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07153471) (`ctg-observation-nct07153471-2026-10-08-73cc3099cfd4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07153471." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07153471-orforglipron-v1 SHA-256: 2edfa2430268ff4277c37daae8646da3ffb45d7c678c106122a7e9e71d67498b.

---

<a id="clinicaltrials-gov-nct07202884-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT07202884

> PeptideScanner retained ClinicalTrials.gov record NCT07202884 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct07202884-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07202884-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07202884-orforglipron-v1
- Content SHA-256: `fdf460146909e39aa338594b528d196ac0d582bd15f51de9993b7c1e583e04be`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07202884 ([`ctg-observation-nct07202884-2026-11-04-17e85677abc4`](#source-ctg-observation-nct07202884-2026-11-04-17e85677abc4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07202884 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07202884-2026-11-04-17e85677abc4`](#source-ctg-observation-nct07202884-2026-11-04-17e85677abc4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07202884 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07202884-2026-11-04-17e85677abc4`](#source-ctg-observation-nct07202884-2026-11-04-17e85677abc4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07202884-2026-11-04-17e85677abc4`](#source-ctg-observation-nct07202884-2026-11-04-17e85677abc4))

### Sources

<a id="source-ctg-observation-nct07202884-2026-11-04-17e85677abc4"></a>
- **ClinicalTrials.gov record NCT07202884 · retained source version 2026-11-04:17e85677abc422d3564998626714b1e33483add7ba467c7c9506ec0f19767e0e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07202884) (`ctg-observation-nct07202884-2026-11-04-17e85677abc4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07202884." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07202884-orforglipron-v1 SHA-256: fdf460146909e39aa338594b528d196ac0d582bd15f51de9993b7c1e583e04be.

---

<a id="clinicaltrials-gov-nct07223593-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT07223593

> PeptideScanner retained ClinicalTrials.gov record NCT07223593 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct07223593-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07223593-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07223593-orforglipron-v1
- Content SHA-256: `a3a3e57129f88d2d4ae72169eafddedf356799cb0899acab843520f1a4bfebe6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07223593 ([`ctg-observation-nct07223593-2026-11-04-18f4ded49c3c`](#source-ctg-observation-nct07223593-2026-11-04-18f4ded49c3c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07223593 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07223593-2026-11-04-18f4ded49c3c`](#source-ctg-observation-nct07223593-2026-11-04-18f4ded49c3c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07223593 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07223593-2026-11-04-18f4ded49c3c`](#source-ctg-observation-nct07223593-2026-11-04-18f4ded49c3c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07223593-2026-11-04-18f4ded49c3c`](#source-ctg-observation-nct07223593-2026-11-04-18f4ded49c3c))

### Sources

<a id="source-ctg-observation-nct07223593-2026-11-04-18f4ded49c3c"></a>
- **ClinicalTrials.gov record NCT07223593 · retained source version 2026-11-04:18f4ded49c3cbd8d0af32401b632a79b00553b77880aa4a82597620e3e918cdc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07223593) (`ctg-observation-nct07223593-2026-11-04-18f4ded49c3c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07223593." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07223593-orforglipron-v1 SHA-256: a3a3e57129f88d2d4ae72169eafddedf356799cb0899acab843520f1a4bfebe6.

---

<a id="clinicaltrials-gov-nct07241390-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT07241390

> PeptideScanner retained ClinicalTrials.gov record NCT07241390 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct07241390-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07241390-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07241390-orforglipron-v1
- Content SHA-256: `39f298f1f1dc5732574b765cac81d3a6cf25608976d67e089801ef4ff8ab29e4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07241390 ([`ctg-observation-nct07241390-2026-11-04-7598815e1ab4`](#source-ctg-observation-nct07241390-2026-11-04-7598815e1ab4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07241390 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07241390-2026-11-04-7598815e1ab4`](#source-ctg-observation-nct07241390-2026-11-04-7598815e1ab4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07241390 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07241390-2026-11-04-7598815e1ab4`](#source-ctg-observation-nct07241390-2026-11-04-7598815e1ab4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07241390-2026-11-04-7598815e1ab4`](#source-ctg-observation-nct07241390-2026-11-04-7598815e1ab4))

### Sources

<a id="source-ctg-observation-nct07241390-2026-11-04-7598815e1ab4"></a>
- **ClinicalTrials.gov record NCT07241390 · retained source version 2026-11-04:7598815e1ab40597e9bfda0165051eb2d1ccaec035cd8f8aed50b206e3666569** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07241390) (`ctg-observation-nct07241390-2026-11-04-7598815e1ab4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07241390." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07241390-orforglipron-v1 SHA-256: 39f298f1f1dc5732574b765cac81d3a6cf25608976d67e089801ef4ff8ab29e4.

---

<a id="clinicaltrials-gov-nct07613307-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT07613307

> PeptideScanner retained ClinicalTrials.gov record NCT07613307 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct07613307-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07613307-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07613307-orforglipron-v1
- Content SHA-256: `de9d9affc04c708102df06842655be38a06e3df0b35d936101afe7a0874b5639`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07613307 ([`ctg-observation-nct07613307-2026-10-08-da074ba3c544`](#source-ctg-observation-nct07613307-2026-10-08-da074ba3c544))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07613307 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07613307-2026-10-08-da074ba3c544`](#source-ctg-observation-nct07613307-2026-10-08-da074ba3c544))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07613307 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07613307-2026-10-08-da074ba3c544`](#source-ctg-observation-nct07613307-2026-10-08-da074ba3c544))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07613307-2026-10-08-da074ba3c544`](#source-ctg-observation-nct07613307-2026-10-08-da074ba3c544))

### Sources

<a id="source-ctg-observation-nct07613307-2026-10-08-da074ba3c544"></a>
- **ClinicalTrials.gov record NCT07613307 · retained source version 2026-10-08:da074ba3c544b62bbf705c8d6a596933b9cfda279095f95639d486c1b582da69** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07613307) (`ctg-observation-nct07613307-2026-10-08-da074ba3c544`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07613307." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07613307-orforglipron-v1 SHA-256: de9d9affc04c708102df06842655be38a06e3df0b35d936101afe7a0874b5639.

---

<a id="clinicaltrials-gov-nct07729332-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT07729332

> PeptideScanner retained ClinicalTrials.gov record NCT07729332 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct07729332-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07729332-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07729332-orforglipron-v1
- Content SHA-256: `20dc0c52ba04bb572cb5a24ac7d41f10dececfee779bd6852a8bf973a859ad6e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07729332 ([`ctg-observation-nct07729332-2026-07-27-e9ddfb04faa8`](#source-ctg-observation-nct07729332-2026-07-27-e9ddfb04faa8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07729332 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07729332-2026-07-27-e9ddfb04faa8`](#source-ctg-observation-nct07729332-2026-07-27-e9ddfb04faa8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07729332 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07729332-2026-07-27-e9ddfb04faa8`](#source-ctg-observation-nct07729332-2026-07-27-e9ddfb04faa8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07729332-2026-07-27-e9ddfb04faa8`](#source-ctg-observation-nct07729332-2026-07-27-e9ddfb04faa8))

### Sources

<a id="source-ctg-observation-nct07729332-2026-07-27-e9ddfb04faa8"></a>
- **ClinicalTrials.gov record NCT07729332 · retained source version 2026-07-27:e9ddfb04faa89848ce642232f09d58fa3ba2e688b272537a82eec0dc36eb6f29** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07729332) (`ctg-observation-nct07729332-2026-07-27-e9ddfb04faa8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07729332." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07729332-orforglipron-v1 SHA-256: 20dc0c52ba04bb572cb5a24ac7d41f10dececfee779bd6852a8bf973a859ad6e.

---

<a id="clinicaltrials-gov-nct07739537-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT07739537

> PeptideScanner retained ClinicalTrials.gov record NCT07739537 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct07739537-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07739537-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07739537-orforglipron-v1
- Content SHA-256: `af0df9a60fd36daa73de5e48b215065e42475b3b9b8832e6f31433dabf0f0f2e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07739537 ([`ctg-observation-nct07739537-2026-08-31-ef00ba8e4037`](#source-ctg-observation-nct07739537-2026-08-31-ef00ba8e4037))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07739537 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07739537-2026-08-31-ef00ba8e4037`](#source-ctg-observation-nct07739537-2026-08-31-ef00ba8e4037))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07739537 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07739537-2026-08-31-ef00ba8e4037`](#source-ctg-observation-nct07739537-2026-08-31-ef00ba8e4037))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07739537-2026-08-31-ef00ba8e4037`](#source-ctg-observation-nct07739537-2026-08-31-ef00ba8e4037))

### Sources

<a id="source-ctg-observation-nct07739537-2026-08-31-ef00ba8e4037"></a>
- **ClinicalTrials.gov record NCT07739537 · retained source version 2026-08-31:ef00ba8e40376d8e591b70e48181c6d11bc6ad50d3b36b087a510e683879f2ac** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07739537) (`ctg-observation-nct07739537-2026-08-31-ef00ba8e4037`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07739537." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07739537-orforglipron-v1 SHA-256: af0df9a60fd36daa73de5e48b215065e42475b3b9b8832e6f31433dabf0f0f2e.

---

<a id="clinicaltrials-gov-nct07790861-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT07790861

> PeptideScanner retained ClinicalTrials.gov record NCT07790861 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct07790861-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07790861-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07790861-orforglipron-v1
- Content SHA-256: `d06c4e550a21b86fab3ee42885aaa26e8fdf9ed79ab8028815dddd527d4057cb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07790861 ([`ctg-observation-nct07790861-2026-10-13-59e712ae7623`](#source-ctg-observation-nct07790861-2026-10-13-59e712ae7623))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07790861 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07790861-2026-10-13-59e712ae7623`](#source-ctg-observation-nct07790861-2026-10-13-59e712ae7623))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07790861 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07790861-2026-10-13-59e712ae7623`](#source-ctg-observation-nct07790861-2026-10-13-59e712ae7623))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07790861-2026-10-13-59e712ae7623`](#source-ctg-observation-nct07790861-2026-10-13-59e712ae7623))

### Sources

<a id="source-ctg-observation-nct07790861-2026-10-13-59e712ae7623"></a>
- **ClinicalTrials.gov record NCT07790861 · retained source version 2026-10-13:59e712ae7623621d03b7d660582b3f34f771aa4e6fb476a03d2a9d1276166e38** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07790861) (`ctg-observation-nct07790861-2026-10-13-59e712ae7623`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07790861." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07790861-orforglipron-v1 SHA-256: d06c4e550a21b86fab3ee42885aaa26e8fdf9ed79ab8028815dddd527d4057cb.

---

<a id="clinicaltrials-gov-nct07794579-orforglipron-v1"></a>

## ClinicalTrials.gov record NCT07794579

> PeptideScanner retained ClinicalTrials.gov record NCT07794579 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was orforglipron.

- Evidence object: `story:clinicaltrials-gov-nct07794579-orforglipron:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07794579-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07794579-orforglipron-v1
- Content SHA-256: `385dff3c75537a16f4f8cb9d49a147957b5b293186cb51bad1aea39f6e7914e2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07794579 ([`ctg-observation-nct07794579-2026-11-05-fd16413a3c90`](#source-ctg-observation-nct07794579-2026-11-05-fd16413a3c90))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07794579 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07794579-2026-11-05-fd16413a3c90`](#source-ctg-observation-nct07794579-2026-11-05-fd16413a3c90))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07794579 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was orforglipron. ([`ctg-observation-nct07794579-2026-11-05-fd16413a3c90`](#source-ctg-observation-nct07794579-2026-11-05-fd16413a3c90))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07794579-2026-11-05-fd16413a3c90`](#source-ctg-observation-nct07794579-2026-11-05-fd16413a3c90))

### Sources

<a id="source-ctg-observation-nct07794579-2026-11-05-fd16413a3c90"></a>
- **ClinicalTrials.gov record NCT07794579 · retained source version 2026-11-05:fd16413a3c904ff5aaba36b0313aafa4a3344173f74dc7d4f29aee53a14e5d0e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07794579) (`ctg-observation-nct07794579-2026-11-05-fd16413a3c90`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07794579." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#clinicaltrials-gov-nct07794579-orforglipron-v1 SHA-256: 385dff3c75537a16f4f8cb9d49a147957b5b293186cb51bad1aea39f6e7914e2.

---

<a id="fda-drugs-nda220934-v1"></a>

## Drugs@FDA application NDA220934

> The official Drugs@FDA dataset lists original submission 1 for NDA 220934 with status AP dated 2026-04-01, and names orforglipron calcium among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda220934:v1`
- Evidence domain: Regulatory
- Date in source: 2026-04-01
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda220934/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#fda-drugs-nda220934-v1
- Content SHA-256: `9a8fc9d91246ed08ba6aad028ef2fb9229f18d99a43a4b3d4bc75be8031219f3`

### Claims and source pins

#### Headline

Drugs@FDA application NDA220934 ([`fda-drugs-nda220934-2026-04-01-182b743dabc5`](#source-fda-drugs-nda220934-2026-04-01-182b743dabc5))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 220934 with status AP dated 2026-04-01, and names orforglipron calcium among the application record's active ingredients. ([`fda-drugs-nda220934-2026-04-01-182b743dabc5`](#source-fda-drugs-nda220934-2026-04-01-182b743dabc5))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 220934 with status AP dated 2026-04-01, and names orforglipron calcium among the application record's active ingredients. ([`fda-drugs-nda220934-2026-04-01-182b743dabc5`](#source-fda-drugs-nda220934-2026-04-01-182b743dabc5))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda220934-2026-04-01-182b743dabc5`](#source-fda-drugs-nda220934-2026-04-01-182b743dabc5))

### Sources

<a id="source-fda-drugs-nda220934-2026-04-01-182b743dabc5"></a>
- **Drugs@FDA application NDA220934 · original submission status AP · 2026-04-01 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA220934%22&limit=1) (`fda-drugs-nda220934-2026-04-01-182b743dabc5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA220934." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#fda-drugs-nda220934-v1 SHA-256: 9a8fc9d91246ed08ba6aad028ef2fb9229f18d99a43a4b3d4bc75be8031219f3.

---

<a id="pubmed-pmid-38091541-orforglipron-v1"></a>

## GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

> PubMed lists PMID 38091541 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38091541-orforglipron:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38091541-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#pubmed-pmid-38091541-orforglipron-v1
- Content SHA-256: `ffb5f3012961c3a99cf75ffff73e20b202ce7b1c4f98acc775d5a60228ed24dc`

### Claims and source pins

#### Headline

GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. ([`pubmed-observation-pmid-38091541-2025-07-03-3db59e0d4464`](#source-pubmed-observation-pmid-38091541-2025-07-03-3db59e0d4464))

#### Summary

PubMed lists PMID 38091541 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38091541-2025-07-03-3db59e0d4464`](#source-pubmed-observation-pmid-38091541-2025-07-03-3db59e0d4464))

#### Paragraph 1

PubMed lists PMID 38091541 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38091541-2025-07-03-3db59e0d4464`](#source-pubmed-observation-pmid-38091541-2025-07-03-3db59e0d4464))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38091541-2025-07-03-3db59e0d4464`](#source-pubmed-observation-pmid-38091541-2025-07-03-3db59e0d4464))

### Sources

<a id="source-pubmed-observation-pmid-38091541-2025-07-03-3db59e0d4464"></a>
- **GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. · retained source version 1:2025-07-03:current:3db59e0d44641ad8eaa5029f3754395bce7e2654d165ac66f318be75c2f9c38b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38091541/) (`pubmed-observation-pmid-38091541-2025-07-03-3db59e0d4464`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "GLP-1 Receptor Agonist Orforglipron for Adults with Obesity." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#pubmed-pmid-38091541-orforglipron-v1 SHA-256: ffb5f3012961c3a99cf75ffff73e20b202ce7b1c4f98acc775d5a60228ed24dc.

---

<a id="pubmed-pmid-38091542-orforglipron-v1"></a>

## GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

> PubMed lists PMID 38091542 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38091542-orforglipron:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38091542-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#pubmed-pmid-38091542-orforglipron-v1
- Content SHA-256: `c2ba6c5b24aa4a103e1b878e96c385439f0b0b873b849bf7a7c9ab0d15108cb4`

### Claims and source pins

#### Headline

GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. ([`pubmed-observation-pmid-38091542-2025-07-03-9bd704fa04e5`](#source-pubmed-observation-pmid-38091542-2025-07-03-9bd704fa04e5))

#### Summary

PubMed lists PMID 38091542 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38091542-2025-07-03-9bd704fa04e5`](#source-pubmed-observation-pmid-38091542-2025-07-03-9bd704fa04e5))

#### Paragraph 1

PubMed lists PMID 38091542 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38091542-2025-07-03-9bd704fa04e5`](#source-pubmed-observation-pmid-38091542-2025-07-03-9bd704fa04e5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38091542-2025-07-03-9bd704fa04e5`](#source-pubmed-observation-pmid-38091542-2025-07-03-9bd704fa04e5))

### Sources

<a id="source-pubmed-observation-pmid-38091542-2025-07-03-9bd704fa04e5"></a>
- **GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. · retained source version 1:2025-07-03:current:9bd704fa04e5ac5b7fd5df4152a66fbcfcb6c5d0ba13474f1b8e68ebe1d518a2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38091542/) (`pubmed-observation-pmid-38091542-2025-07-03-9bd704fa04e5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "GLP-1 Receptor Agonist Orforglipron for Adults with Obesity." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#pubmed-pmid-38091542-orforglipron-v1 SHA-256: c2ba6c5b24aa4a103e1b878e96c385439f0b0b873b849bf7a7c9ab0d15108cb4.

---

<a id="pubmed-pmid-38091543-orforglipron-v1"></a>

## GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.

> PubMed lists PMID 38091543 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38091543-orforglipron:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38091543-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#pubmed-pmid-38091543-orforglipron-v1
- Content SHA-256: `93b3ba28e87eb0d55866ebe36275c6f81658e4beea4dc2a267db57518e2be7f2`

### Claims and source pins

#### Headline

GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply. ([`pubmed-observation-pmid-38091543-2025-07-01-4a666e4fc135`](#source-pubmed-observation-pmid-38091543-2025-07-01-4a666e4fc135))

#### Summary

PubMed lists PMID 38091543 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38091543-2025-07-01-4a666e4fc135`](#source-pubmed-observation-pmid-38091543-2025-07-01-4a666e4fc135))

#### Paragraph 1

PubMed lists PMID 38091543 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-12-14 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38091543-2025-07-01-4a666e4fc135`](#source-pubmed-observation-pmid-38091543-2025-07-01-4a666e4fc135))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38091543-2025-07-01-4a666e4fc135`](#source-pubmed-observation-pmid-38091543-2025-07-01-4a666e4fc135))

### Sources

<a id="source-pubmed-observation-pmid-38091543-2025-07-01-4a666e4fc135"></a>
- **GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply. · retained source version 1:2025-07-01:current:4a666e4fc1356751f3aebf7f2a6e59029b863800b0cb2310413d619e7fcab6ae** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38091543/) (`pubmed-observation-pmid-38091543-2025-07-01-4a666e4fc135`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#pubmed-pmid-38091543-orforglipron-v1 SHA-256: 93b3ba28e87eb0d55866ebe36275c6f81658e4beea4dc2a267db57518e2be7f2.

---

<a id="pubmed-pmid-41994902-orforglipron-v1"></a>

## Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.

> PubMed lists PMID 41994902 in Diabetes, obesity & metabolism as Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41994902-orforglipron:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41994902-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#pubmed-pmid-41994902-orforglipron-v1
- Content SHA-256: `53f50b3fd7a329a2259f392335bf5e3f640b89eeacfd982c5ea964f021266597`

### Claims and source pins

#### Headline

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight. ([`pubmed-observation-pmid-41994902-2026-11-09-7e79a17dba97`](#source-pubmed-observation-pmid-41994902-2026-11-09-7e79a17dba97))

#### Summary

PubMed lists PMID 41994902 in Diabetes, obesity & metabolism as Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41994902-2026-11-09-7e79a17dba97`](#source-pubmed-observation-pmid-41994902-2026-11-09-7e79a17dba97))

#### Paragraph 1

PubMed lists PMID 41994902 in Diabetes, obesity & metabolism as Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41994902-2026-11-09-7e79a17dba97`](#source-pubmed-observation-pmid-41994902-2026-11-09-7e79a17dba97))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41994902-2026-11-09-7e79a17dba97`](#source-pubmed-observation-pmid-41994902-2026-11-09-7e79a17dba97))

### Sources

<a id="source-pubmed-observation-pmid-41994902-2026-11-09-7e79a17dba97"></a>
- **Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight. · retained source version 1:2026-11-09:current:7e79a17dba975a39311b82eb639465e6b053d44d8b0d0f29b1691d277bcb33aa** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41994902/) (`pubmed-observation-pmid-41994902-2026-11-09-7e79a17dba97`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#pubmed-pmid-41994902-orforglipron-v1 SHA-256: 53f50b3fd7a329a2259f392335bf5e3f640b89eeacfd982c5ea964f021266597.

---

<a id="pubmed-pmid-42138709-orforglipron-v1"></a>

## Orforglipron Calcium.

> PubMed lists PMID 42138709 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2026-07-22 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42138709-orforglipron:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42138709-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#pubmed-pmid-42138709-orforglipron-v1
- Content SHA-256: `db0775d5648bf204d3d8fc12cb85afa82d073118f372fc4ab0727e6b53095767`

### Claims and source pins

#### Headline

Orforglipron Calcium. ([`pubmed-observation-pmid-42138709-2026-07-21-7dbfb1366aab`](#source-pubmed-observation-pmid-42138709-2026-07-21-7dbfb1366aab))

#### Summary

PubMed lists PMID 42138709 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2026-07-22 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42138709-2026-07-21-7dbfb1366aab`](#source-pubmed-observation-pmid-42138709-2026-07-21-7dbfb1366aab))

#### Paragraph 1

PubMed lists PMID 42138709 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2026-07-22 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42138709-2026-07-21-7dbfb1366aab`](#source-pubmed-observation-pmid-42138709-2026-07-21-7dbfb1366aab))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42138709-2026-07-21-7dbfb1366aab`](#source-pubmed-observation-pmid-42138709-2026-07-21-7dbfb1366aab))

### Sources

<a id="source-pubmed-observation-pmid-42138709-2026-07-21-7dbfb1366aab"></a>
- **Orforglipron Calcium. · retained source version 1:2026-07-21:current:7dbfb1366aab33686ed272e59f14a92445aff8390e2c8d361a41c4bf10b907e3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42138709/) (`pubmed-observation-pmid-42138709-2026-07-21-7dbfb1366aab`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Orforglipron Calcium." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#pubmed-pmid-42138709-orforglipron-v1 SHA-256: db0775d5648bf204d3d8fc12cb85afa82d073118f372fc4ab0727e6b53095767.

---

<a id="pubmed-pmid-42420063-orforglipron-v1"></a>

## Orforglipron (Foundayo) for adults with obesity.

> PubMed lists PMID 42420063 in Trends in pharmacological sciences as Journal Article, with publication-date metadata of 2026-07-08 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42420063-orforglipron:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42420063-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#pubmed-pmid-42420063-orforglipron-v1
- Content SHA-256: `098386e9d817b6c33391a14abbdaf8372aa79e43134b1bbe297ee5b9d749fe21`

### Claims and source pins

#### Headline

Orforglipron (Foundayo) for adults with obesity. ([`pubmed-observation-pmid-42420063-2026-08-06-94a855d423a0`](#source-pubmed-observation-pmid-42420063-2026-08-06-94a855d423a0))

#### Summary

PubMed lists PMID 42420063 in Trends in pharmacological sciences as Journal Article, with publication-date metadata of 2026-07-08 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42420063-2026-08-06-94a855d423a0`](#source-pubmed-observation-pmid-42420063-2026-08-06-94a855d423a0))

#### Paragraph 1

PubMed lists PMID 42420063 in Trends in pharmacological sciences as Journal Article, with publication-date metadata of 2026-07-08 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42420063-2026-08-06-94a855d423a0`](#source-pubmed-observation-pmid-42420063-2026-08-06-94a855d423a0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42420063-2026-08-06-94a855d423a0`](#source-pubmed-observation-pmid-42420063-2026-08-06-94a855d423a0))

### Sources

<a id="source-pubmed-observation-pmid-42420063-2026-08-06-94a855d423a0"></a>
- **Orforglipron (Foundayo) for adults with obesity. · retained source version 1:2026-08-06:current:94a855d423a083ec87a13766380afdeebe125313cba78f0511d637c82e6ada01** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42420063/) (`pubmed-observation-pmid-42420063-2026-08-06-94a855d423a0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Orforglipron (Foundayo) for adults with obesity." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#pubmed-pmid-42420063-orforglipron-v1 SHA-256: 098386e9d817b6c33391a14abbdaf8372aa79e43134b1bbe297ee5b9d749fe21.

---

<a id="pubmed-pmid-43002163-orforglipron-v1"></a>

## Orforglipron for Obstructive Sleep Apnea: Research Summary.

> PubMed lists PMID 43002163 in JAMA as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-43002163-orforglipron:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-43002163-orforglipron/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#pubmed-pmid-43002163-orforglipron-v1
- Content SHA-256: `d0151b1879be88d35857d308d805fd0e6bea31325e869e4444896a9a5a762535`

### Claims and source pins

#### Headline

Orforglipron for Obstructive Sleep Apnea: Research Summary. ([`pubmed-observation-pmid-43002163-2026-11-09-ba425677421c`](#source-pubmed-observation-pmid-43002163-2026-11-09-ba425677421c))

#### Summary

PubMed lists PMID 43002163 in JAMA as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43002163-2026-11-09-ba425677421c`](#source-pubmed-observation-pmid-43002163-2026-11-09-ba425677421c))

#### Paragraph 1

PubMed lists PMID 43002163 in JAMA as Journal Article, with publication-date metadata of 2026-11-09 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43002163-2026-11-09-ba425677421c`](#source-pubmed-observation-pmid-43002163-2026-11-09-ba425677421c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-43002163-2026-11-09-ba425677421c`](#source-pubmed-observation-pmid-43002163-2026-11-09-ba425677421c))

### Sources

<a id="source-pubmed-observation-pmid-43002163-2026-11-09-ba425677421c"></a>
- **Orforglipron for Obstructive Sleep Apnea: Research Summary. · retained source version 1:2026-11-09:current:ba425677421c9e44b371fa974670d5e862809cc59f2d51789704674af9e633de** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/43002163/) (`pubmed-observation-pmid-43002163-2026-11-09-ba425677421c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Orforglipron for Obstructive Sleep Apnea: Research Summary." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/orforglipron.json#pubmed-pmid-43002163-orforglipron-v1 SHA-256: d0151b1879be88d35857d308d805fd0e6bea31325e869e4444896a9a5a762535.

